-
Tulisokibart bests placebo, may yield ‘important clinical benefit’ via TL1A blockade in UC
26 Sep 2024 17:41 GMT
… results suggest that important clinical benefit may be achieved through TL1A … , Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca …
-
DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight
25 Jun 2025 22:36 GMT
… , respectively. It has shown therapeutic benefit in earlier Phase II trials … key ulcerative colitis companies, including Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex …
-
Pfizer Completes Acquisition of Arena Pharmaceuticals
12 Mar 2022 06:52 GMT
… completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing … growth potential, including their potential benefits, that involve substantial risks and … ability to realize the anticipated benefits of the acquisition, including the …
-
Pfizer Completes Acquisition of Arena Pharmaceuticals
11 Mar 2022 13:34 GMT
… completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing … growth potential, including their potential benefits, that involve substantial risks and … ability to realize the anticipated benefits of the acquisition, including the …
-
Pfizer to Acquire Arena Pharmaceuticals
13 Dec 2021 11:45 GMT
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced … Etrasimod also demonstrated a favorable benefit/risk profile, consistent with … growth potential, including their potential benefits, that involve substantial risks and …
-
Arena Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Arena Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARNA
13 Dec 2021 15:00 GMT
… investigating whether the sale of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) to Pfizer … transaction, or other relief and benefits.
Halper Sadeh encourages Arena shareholders …
-
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
19 Nov 2021 13:30 GMT
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today … in any country.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a … , statements about the potential benefits of the CULTIVATE trial, … Study A, the potential benefits of etrasimod, and Arena’ …
-
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
02 Sep 2021 12:30 GMT
… President and Chief Commercial Officer, Arena Pharmaceuticals
William Sandborn, MD, Distinguished … in any country.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a … limitation, statements about the potential benefits of etrasimod, and Arena’ …
-
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
02 Sep 2021 12:30 GMT
… President and Chief Commercial Officer, Arena Pharmaceuticals
William Sandborn, MD, Distinguished … in any country.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a … limitation, statements about the potential benefits of etrasimod, and Arena’ …
-
Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight
10 Jun 2025 17:00 GMT
… GLA gene mutations, offering benefits to 35–50% of patients … Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, among others. Crohn’ … Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo …
About
© 1995-2025